Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.59 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PAM | P19021 | 2/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27894869 | 0.97 | DGKA (0.61) | DGKADNM1CYP3A4TSHRATM | |
| SCHEMBL18429952 | 0.97 | DGKA (0.65) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL27872160 | 0.93 | DGKA (0.65) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL8815475 | 0.93 | DGKA (0.65) | DGKADNM1PRSS1PRSS2PRSS3 | |
| Cetyl Palmitate SCHEMBL8815494 | 0.93 | DGKA (0.65) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL27819627 | 0.93 | DGKA (0.65) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL27872169 | 0.93 | DGKA (0.65) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL9637091 | 0.93 | DGKA (0.65) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL495796 | 0.92 | DGKA (0.58) | DGKADNM1CYP3A4TSHRATM | |
| SCHEMBL494852 | 0.92 | DGKA (0.58) | DGKADNM1CYP3A4TSHRATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 434 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4380572-A1 | FORMULATION FOR SUBSTITUTED 2-AMINOTHIAZOLES IN THE TREATMENT OF FUNGAL AND FUNGAL-BACTERIAL INFECTIONS OF THE NAIL | OnychoPharm GmbH (DE) | 2024-06-12 | — | — | EP | claimed |
| WO-2023198695-A1 | MATERIAL HAVING A BARRIER LAYER COMPRISING LIGNOSULFONATE | KEMIRA OYJ (FI) | 2023-10-19 | — | — | WO | claimed |
| US-11744803-B2 | PH-controlled pulsatile delivery system, methods for preparation and use thereof | Stichting Groningen Centre for Drug Rese (NL) | 2023-09-05 | — | — | US | claimed |
| US-20230255892-A1 | OSMOTIC DRUG DELIVERY SYSTEM | SUPERNUS PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | claimed |
| US-20230248667-A1 | EXTENDED RELEASE COMPOSITIONS OF PSEUDOEPHEDRINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | AUROBINDO PHARMA LTD (IN) | 2023-08-10 | — | — | US | claimed |
| WO-2023011750-A1 | FORMULATION FOR SUBSTITUTED 2-AMINOTHIAZOLES IN THE TREATMENT OF FUNGAL AND FUNGAL-BACTERIAL INFECTIONS OF THE NAIL | ONYCHOPHARM GMBH (DE) | 2023-02-09 | — | — | WO | claimed |
| EP-4129292-A1 | FORMULATION FOR SUBSTITUTED 2-AMINOTHIAZOLES IN THE TREATMENT OF FUNGAL AND FUNGAL-BACTERIAL INFECTIONS OF THE NAIL | OnychoPharm GmbH (DE) | 2023-02-08 | — | — | EP | claimed |
| CN-115666533-A | Enteric coated formulation containing pirfenidone with improved safety and stability and method of making the same | 永进药品工业株式会社 | 2023-01-31 | — | — | CN | claimed |
| US-20220287980-A1 | PHARMACEUTICAL COMPOSITION AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2022-09-15 | — | — | US | claimed |
| EP-1916995-B2 | PH-CONTROLLED PULSATILE DELIVERY SYSTEM, METHODS FOR PREPARATION AND USE THEREOF | STICHTING GRONINGEN CENTRE FOR DRUG RES (NL) | 2022-06-29 | — | — | EP | claimed |
| US-20100173921-A1 | Antiretroviral Solid Oral Composition | CIPLA LIMITED (IN) | 2010-07-08 | — | — | US | claimed |
| US-7611728-B2 | Osmotic delivery of therapeutic compounds by solubility enhancement | SUPERNUS PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | claimed |
| US-20090181089-A1 | PH-Controlled Pulsatile Delivery System, Methods for Preparation and Use Thereof | STICHTING GRONINGEN CENTRE FOR DRUG RESEARCH (NL) | 2009-07-16 | — | — | US | claimed |
| EP-1916995-A1 | PH-CONTROLLED PULSATILE DELIVERY SYSTEM, METHODS FOR PREPARATION AND USE THEREOF | Stichting Groningen Centre for Drug Research (NL) | 2008-05-07 | — | — | EP | claimed |
| WO-2008017867-A2 | ANTIRETROVIRAL SOLID ORAL COMPOSITION WITH AT LEAST ONE WATER INSOLUBLE POLYMER | CIPLA LIMITED (IN) | 2008-02-14 | — | — | WO | claimed |
| WO-2007013794-A1 | PH-CONTROLLED PULSATILE DELIVERY SYSTEM, METHODS FOR PREPARATION AND USE THEREOF | STICHTING GRONINGEN CENTRE FOR DRUG RESEARCH (NL) | 2007-02-01 | — | — | WO | claimed |
| EP-1660051-A1 | OSMOTIC DELIVERY OF THERAPEUTIC COMPOUNDS BY SOLUBILITY ENHANCEMENT | Shire Laboratories Inc. (US) | 2006-05-31 | — | — | EP | claimed |
| WO-2005023228-A1 | OSMOTIC DELIVERY OF THERAPEUTIC COMPOUNDS BY SOLUBILITY ENHANCEMENT | SHIRE LABORATORIES, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| US-20050053653-A1 | delivering hydrobhobic drug containing meglumine as solubilizing agent; controlled release | SUPERNUS PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | claimed |
| EP-1098635-B1 | ENTERIC COATED PHARMACEUTICAL TABLET CONTAINING DIDANOSINE | BRISTOL MYERS SQUIBB CO (US) | 2004-06-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220287980-A1 | PHARMACEUTICAL COMPOSITION AND USES THEREOF | DPP4, SLC5A2, SLC5A1 | DGKA 3658/4885DNM1 3586/4885CYP3A4 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.